vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and FIRSTSUN CAPITAL BANCORP (FSUN). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $110.0M, roughly 1.3× FIRSTSUN CAPITAL BANCORP). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 19.6%, a 15.9% gap on every dollar of revenue. Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 6.9%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
FirstSun Capital Bancorp is a U.S.-headquartered financial holding company that offers a comprehensive range of banking and financial services, including commercial and consumer lending, deposit products, wealth management, and treasury solutions. It mainly serves individual customers, small and medium-sized enterprises, and corporate clients across U.S. regional markets.
ADMA vs FSUN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $110.0M |
| Net Profit | $49.4M | $21.6M |
| Gross Margin | 63.8% | — |
| Operating Margin | 45.1% | — |
| Net Margin | 35.5% | 19.6% |
| Revenue YoY | 18.4% | — |
| Net Profit YoY | -55.9% | -8.4% |
| EPS (diluted) | $0.20 | $0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $110.0M | ||
| Q4 25 | $139.2M | $110.2M | ||
| Q3 25 | $134.2M | $107.3M | ||
| Q2 25 | $122.0M | $105.6M | ||
| Q1 25 | $114.8M | $96.2M | ||
| Q4 24 | $117.5M | $98.7M | ||
| Q3 24 | $119.8M | $98.2M | ||
| Q2 24 | $107.2M | $96.2M |
| Q1 26 | — | $21.6M | ||
| Q4 25 | $49.4M | $24.8M | ||
| Q3 25 | $36.4M | $23.2M | ||
| Q2 25 | $34.2M | $26.4M | ||
| Q1 25 | $26.9M | $23.6M | ||
| Q4 24 | $111.9M | $16.4M | ||
| Q3 24 | $35.9M | $22.4M | ||
| Q2 24 | $32.1M | $24.6M |
| Q1 26 | — | — | ||
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | — | ||
| Q2 25 | 55.1% | — | ||
| Q1 25 | 53.2% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 49.8% | — | ||
| Q2 24 | 53.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 45.1% | 29.0% | ||
| Q3 25 | 38.0% | 26.4% | ||
| Q2 25 | 35.1% | 31.2% | ||
| Q1 25 | 30.4% | 30.9% | ||
| Q4 24 | 32.6% | 20.4% | ||
| Q3 24 | 33.1% | 29.1% | ||
| Q2 24 | 36.6% | 32.3% |
| Q1 26 | — | 19.6% | ||
| Q4 25 | 35.5% | 22.5% | ||
| Q3 25 | 27.1% | 21.6% | ||
| Q2 25 | 28.1% | 25.0% | ||
| Q1 25 | 23.4% | 24.5% | ||
| Q4 24 | 95.2% | 16.6% | ||
| Q3 24 | 30.0% | 22.8% | ||
| Q2 24 | 29.9% | 25.5% |
| Q1 26 | — | $0.76 | ||
| Q4 25 | $0.20 | $0.89 | ||
| Q3 25 | $0.15 | $0.82 | ||
| Q2 25 | $0.14 | $0.93 | ||
| Q1 25 | $0.11 | $0.83 | ||
| Q4 24 | $0.45 | $0.57 | ||
| Q3 24 | $0.15 | $0.79 | ||
| Q2 24 | $0.13 | $0.88 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $413.7M |
| Total DebtLower is stronger | $72.1M | — |
| Stockholders' EquityBook value | $477.3M | $1.2B |
| Total Assets | $624.2M | $8.6B |
| Debt / EquityLower = less leverage | 0.15× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $413.7M | ||
| Q4 25 | $87.6M | $652.6M | ||
| Q3 25 | $61.4M | $659.9M | ||
| Q2 25 | $90.3M | $785.1M | ||
| Q1 25 | $71.6M | $621.4M | ||
| Q4 24 | $103.1M | $615.9M | ||
| Q3 24 | $86.7M | $573.7M | ||
| Q2 24 | $88.2M | $535.8M |
| Q1 26 | — | — | ||
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $72.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $477.3M | $1.2B | ||
| Q3 25 | $431.2M | $1.1B | ||
| Q2 25 | $398.3M | $1.1B | ||
| Q1 25 | $373.4M | $1.1B | ||
| Q4 24 | $349.0M | $1.0B | ||
| Q3 24 | $231.9M | $1.0B | ||
| Q2 24 | $188.3M | $996.6M |
| Q1 26 | — | $8.6B | ||
| Q4 25 | $624.2M | $8.5B | ||
| Q3 25 | $568.7M | $8.5B | ||
| Q2 25 | $558.4M | $8.4B | ||
| Q1 25 | $510.6M | $8.2B | ||
| Q4 24 | $488.7M | $8.1B | ||
| Q3 24 | $390.6M | $8.1B | ||
| Q2 24 | $376.4M | $8.0B |
| Q1 26 | — | — | ||
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | — |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $35.6M | $111.5M | ||
| Q3 25 | $13.3M | $49.4M | ||
| Q2 25 | $21.1M | $15.0M | ||
| Q1 25 | $-19.7M | $26.4M | ||
| Q4 24 | $50.2M | $101.1M | ||
| Q3 24 | $25.0M | $48.1M | ||
| Q2 24 | $45.6M | $20.9M |
| Q1 26 | — | — | ||
| Q4 25 | $34.6M | $104.0M | ||
| Q3 25 | $-1.1M | $47.6M | ||
| Q2 25 | $18.7M | $13.0M | ||
| Q1 25 | $-24.4M | $24.3M | ||
| Q4 24 | $47.5M | $95.7M | ||
| Q3 24 | $24.0M | $47.1M | ||
| Q2 24 | $43.6M | $19.9M |
| Q1 26 | — | — | ||
| Q4 25 | 24.8% | 94.3% | ||
| Q3 25 | -0.8% | 44.4% | ||
| Q2 25 | 15.3% | 12.3% | ||
| Q1 25 | -21.2% | 25.3% | ||
| Q4 24 | 40.4% | 97.0% | ||
| Q3 24 | 20.0% | 47.9% | ||
| Q2 24 | 40.7% | 20.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 6.8% | ||
| Q3 25 | 10.7% | 1.6% | ||
| Q2 25 | 2.0% | 1.9% | ||
| Q1 25 | 4.1% | 2.1% | ||
| Q4 24 | 2.3% | 5.5% | ||
| Q3 24 | 0.9% | 1.1% | ||
| Q2 24 | 1.9% | 1.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.72× | 4.49× | ||
| Q3 25 | 0.36× | 2.13× | ||
| Q2 25 | 0.62× | 0.57× | ||
| Q1 25 | -0.73× | 1.12× | ||
| Q4 24 | 0.45× | 6.18× | ||
| Q3 24 | 0.70× | 2.15× | ||
| Q2 24 | 1.42× | 0.85× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
